Product Information
RIVASTIGMINE 13.3 MG/24HR PTCH is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $1.8036 per EA under NDC 00378907293. Its NADAC has been published 420 times since Aug 8, 2018.
FDA first approved this application on Jun 20, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
13.3 mg/24h
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378907293
Classification
Generic
Dosage Form
PATCH
Route
TRANSDERMAL
Effective Date
8/19/2026
Active Ingredients
RIVASTIGMINEApproval Type
Generic (ANDA)
FDA Application
ANDA205622FDA Approved
6/20/2018
TE Code
AB
On Market Since
6/20/2018
Pharmacological Classes
Price Statistics
The NADAC for RIVASTIGMINE 13.3 MG/24HR PTCH has been published 420 times since Aug 8, 2018, and over the history we have for it it has declined 72.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.8036 per EA |
|---|---|
| All-time high | $7.0523 (Oct 10, 2018) |
| All-time low | $1.6436 (Apr 17, 2024) |
| 52-week high | $2.0633 |
| 52-week low | $1.8036 |
| Median price | $2.7992 |
| Average price | $3.1123 |
| Largest weekly change | -33.3% (Apr 17, 2024) |
| Weeks tracked | 420 |
| Tracking since | Aug 8, 2018 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of RIVASTIGMINE 13.3 MG/24HR PTCH?
The current National Average Drug Acquisition Cost (NADAC) for RIVASTIGMINE 13.3 MG/24HR PTCH, manufactured by Mylan Pharmaceuticals Inc., is $1.8036 per EA (NDC 00378907293), effective Aug 19, 2026.
How has the price of RIVASTIGMINE 13.3 MG/24HR PTCH changed over time?
Over the history we have for it, the NADAC for RIVASTIGMINE 13.3 MG/24HR PTCH has declined 72.7%. It has been tracked across 420 weekly CMS publications since Aug 8, 2018.
What are the highest and lowest recorded NADAC prices for RIVASTIGMINE 13.3 MG/24HR PTCH?
Since Aug 8, 2018, the NADAC for RIVASTIGMINE 13.3 MG/24HR PTCH has ranged from a low of $1.6436 (Apr 17, 2024) to a high of $7.0523 (Oct 10, 2018), with a median of $2.7992 per EA.
Are there cheaper alternatives to RIVASTIGMINE 13.3 MG/24HR PTCH?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as RIVASTIGMINE 13.3 MG/24HR PTCH in a comparable dosage form, but none are currently priced below it.
Who manufactures RIVASTIGMINE 13.3 MG/24HR PTCH?
RIVASTIGMINE 13.3 MG/24HR PTCH (NDC 00378907293) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.